Apr 10, 2018 ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease
Apr 3, 2018 ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
Mar 7, 2018 ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants
Mar 6, 2018 ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies
Jan 25, 2018 ProMIS Neurosciences Issues White Paper Entitled: "Not All Amyloid Beta Therapeutics Are Created Equal"
Jan 23, 2018 ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies